N@N

Market Maker Surveillance Report. XOMA, SO, ALTR, ATVI, HGSI, VRML, Highest Net Buy Volume With Lowest Price Friction For Tues

March 6, 2012 / M2 PRESSWIRE / BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Tuesday there were 3395 companies with "abnormal" market making, 1074 companies with positive Friction Factors and 5264 companies with negative Friction Factors. Here is a list of the top companies with the highest net buy volume on Tuesday and lowest price Friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. XOMA LTD (NASDAQ:XOMA), SOUTHERN COMPANY (THE) (NYSE:SO), ALTERA CORP (NASDAQ:ALTR), ACTIVISION BLIZZARD INC (NASDAQ:ATVI), HUMAN GENOME SCIENCES INC (NASDAQ:HGSI), VERMILLION INC (NASDAQ:VRML). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .

Market Maker Friction Factor is shown in the chart below:

     Symbol     Change       Percent      Buy Volume      Buy %%       Sell Volume     Sell %%      Net Volume      Friction
     XOMA       $0.360       24.83%       4,943,896       53.38%       4,168,122       45.00%       775,774         21,549  
     SO         $0.410       0.93%        2,550,284       41.60%       1,978,910       32.28%       571,374         13,936  
     ALTR       $0.560       1.52%        3,699,868       51.89%       3,136,901       43.99%       562,967         10,053  
     ATVI       $0.020       0.17%        7,622,554       56.07%       5,963,610       43.86%       1,658,944       829,472 
     HGSI       $0.250       3.41%        6,456,498       53.79%       5,531,161       46.08%       925,337         37,013  
     VRML       $1.740       130.83%      5,779,485       54.19%       4,880,860       45.76%       898,625         5,165   

Analysis of the Friction Factor chart above shows that each of the six stocks mentioned above have high net dollar gains (Change) and very low price friction in their stocks. The Friction Factor displays how many more shares of buying than selling are required to move a stock higher by one cent or how many more shares of selling than buying moves a stock lower by 1 cent.

For example, the chart above shows XOMA with a Net Buy Volume of 775,774 shares and a Friction Factor of 21,549 shares. That means that it takes 21,549 more shares of buying than selling to move XOMA higher by one penny. This means the Market Makers are allowing the stock to move up higher as of Tuesday (lower friction). And with one of the highest Net Buy Volumes, the combination of low friction and high net buy volume is bullish.

XOMA LTD (NASDAQ:XOMA) - XOMA Ltd., incorporated in 1981, is a biopharmaceutical company in the field of therapeutic antibody discovery and development. The Company has a royalty interest in one approved therapeutic antibody, RAPTIVA, which is marketed in the United States, Europe and elsewhere, for the treatment of moderate-to-severe plaque psoriasis. XOMA also has a future royalty interest in additional therapeutic antibody product candidates being developed by others as a result of licensing its technologies. XOMA's pipeline includes both products and collaborative programs at various stages of preclinical and clinical development primarily directed toward treatments for cancer and immune disorders. In addition to supporting its product pipeline, the Company uses its infrastructure to provide process development and manufacturing services on a fee-for-service basis.

RAPTIVA (Efalizumab)

The Company markets RAPTIVA under an agreement with Genentech, Inc. as a result of a prior collaborative product development program. RAPTIVA is a humanized therapeutic monoclonal antibody developed to treat immune system disorders. RAPTIVA can be self-administered by patients as a single, once-weekly subcutaneous injection. In 2005, Serono had launched RAPTIVA in over 40 countries worldwide.

RAPTIVA competes with Enbrel from Amgen Inc. and its partner Wyeth Pharmaceuticals; Amevive from Biogen Idec Inc.; BG-12 from Biogen Idec Inc. and Fumapharm AG; Remicade from Centocor, Inc. Humira from Abbott Laboratories, and ISA247 from Isotechnika, Inc.

CHIR-12.12

CHIR-12.12, which is being developed by the Company in collaboration with Chiron Corporation, is an anti-CD40 antagonist antibody intended as a treatment for B-cell malignancies. In April 2005, XOMA announced the initiation of Phase I study for patients with advance chronic lymphocytic leukemia (CLL). Then in October 2005, the Company initiated a second Phase I study for patients with multiple myeloma (MM).

NEUPREX (opebacan/rBPI21)

NEUPREX (opebacan/rBPI21) is an injectable formulation of rBPI21, a modified recombinant fragment of human bactericidal/permeability-increasing protein (BPI). BPI is a human host-defense protein made by a type of white blood cell that is involved in the body's defenses against microbial infection. In October of 2003, in conjunction with Children's Medical Center Dallas, the Company announced the initiation of an open-label, single center, dose escalation, investigator-sponsored, Phase I/II clinical trial of NEUPREX in pediatric patients with congenital heart abnormalities requiring open heart surgery associated with cardiopulmonary bypass.

XMA005.2

XMA005.2 is a Human Engineered monoclonal antibody with a high-affinity and potent inhibitory activity against its inflammatory target. This high potency means that it may be suitable for use as a monthly-dose injectable therapeutic. XOMA is evaluating XMA005.2 in preclinical studies targeting multiple indications, including osteoarthritis and rheumatoid arthritis, where less frequent dosing could be a significant marketing advantage.

Anti-gastrin Mab

In September of 2004, XOMA announced a worldwide collaboration with Aphton Corporation to develop treatments for gastrointestinal (GI) and other gastrin-sensitive cancers using anti-gastrin monoclonal antibodies. Gastrin has been shown to be involved in the progression of colorectal, stomach, liver and pancreatic cancers and inhibiting gastrin may inhibit such growth.

Metabolic Disease Target

The Company is co-developing Metabolic Disease Target with Lexicon Genetics. Metabolic Disease Target is a secreted protein involved in metabolic functions such as insulin sensitivity and weight gain that was identified through Lexicon's Knockout Technology. Antibodies to this target may be developed to treat Type II diabetes, obesity and other metabolic diseases.

MLN2222

MLN2222 (also known as CAB2) is being developed by XOMA in partnership with Millennium Pharmaceuticals, Inc. MLN2222 is a complement inhibitor for coronary artery bypass graft surgery tar

SOUTHERN COMPANY (THE) (NYSE:SO) - Southern Company, through its subsidiaries, operates as a utility company that provides electric service in the southeastern United States. The company generates, transmits, and distributes electricity through coal, nuclear, oil and gas, and hydro resources. It offers electric service primarily in Alabama, Georgia, Florida, and Mississippi; and serves approximately 4.4 million retail customers with approximately 42,000 megawatts of generating capacity. Southern Company also constructs, acquires, owns, and manages generation assets and sells electricity in the wholesale market. Its transmission assets include 27,000 miles of transmission lines and 3,400 substations. The company also provides digital wireless communications, such as push to talk, cellular service, text messaging, wireless Internet access, and wireless data to approximately 300,000 subscribers in the southeast; and wholesale fiber optic solutions to telecommunication providers under the name Southern Telecom. The company was founded in 1945 and is headquartered in Atlanta, Georgia.

ALTERA CORP (NASDAQ:ALTR) - Altera Corp. designs, manufactures, and markets programmable logic devices (plds); structured application-specific integrated circuit devices; predefined design building blocks or intellectual-property cores; and associated development tools. Its programmable logic devices are semiconductor integrated circuits. Altera also provides HardCopy, HardCopy II, and other masked programmed logic devices, configuration devices, development software, and other tools and intellectual-property cores. Altera was founded in 1983 and is headquartered in San Jose, Calif.

ACTIVISION BLIZZARD INC (NASDAQ:ATVI) - Activision Blizzard, Inc., through its subsidiaries, publishes online, personal computer (PC), console, and handheld games worldwide. The company develops and publishes PC-based computer games and maintains its proprietary online-game related service, Battle.net. It publishes interactive software products and peripherals. Its products cover various game categories, such as action/adventure, action sports, racing, role-playing, simulation, first-person action, music, and strategy. Activisions products comprise Monsters vs. Aliens, Guitar Hero, X-Men Origins, PROTOTYPE, Transformers, Ice Age, Wolfenstein, Marvel Ultimate Alliance, Bakugan Battle Brawlers, DJ Hero, Band Hero, Call of Duty, Tony Hawk, Guitar Hero, Three map packs for Call of Duty, True Crime, Spider-Man, Bakugan, Blur, and Singularity. Its customers include retail outlets and distributors, including mass-market retailers, consumer electronics stores, discount warehouses, and game specialty stores. Activision Blizzard, Inc. is based in Santa Monica, California.

HUMAN GENOME SCIENCES INC (NASDAQ:HGSI) - Human Genome Sciences, Inc. operates as a biopharmaceutical company. Its principal products in development include BENLYSTA for systemic lupus erythematosus; and raxibacumab for inhalation anthrax. The companys mid- and early-stage pipeline products comprise Mapatumumab for the treatment of non-small cell lung cancer, multiple myeloma, and hepatocellular cancer; IAP Inhibitors that are compounds, which block the activity of IAP (inhibitor of apoptosis) proteins, allowing apoptosis to proceed and causing the cancer cells to die; and CCR5 mAb, a human monoclonal antibody to the CCR5 receptor for the treatment of ulcerative colitis. Human Genome Sciences, Inc. also holds financial rights to certain products in the GlaxoSmithKline clinical development pipeline, including darapladib, a Phase III clinical trial product for the treatment of coronary heart disease and ischemic stroke; and Albiglutide for the treatment for type 2 diabetes, which is in Phase III clinical trial stage. The company has a license agreement with GlaxoSmithKline for the co-development and commercialization of BENLYSTA; and a collaboration and license agreement with Aegera Therapeutics, Inc. to develop and commercialize certain oncology molecules and related backup compounds. Human Genome Sciences, Inc. was founded in 1992 and is headquartered in Rockville, Maryland.

VERMILLION INC (NASDAQ:VRML) - Vermillion, Inc. and its subsidiaries engage in the discovery, development, and commercialization of diagnostics tests that help physicians to diagnose and treat patients. The company develops novel diagnostic tests in the fields of oncology, hematology, cardiology, and womens health with the initial focus on ovarian cancer. Its lead product includes the OVA1 ovarian tumor triage test (the OVA1 Test), which addresses presurgical identification of women who are at high risk of having a malignant ovarian tumor. The company has collaborations with various academic and research institutions, including The Johns Hopkins University School of Medicine; The University of Texas M.D. Anderson Cancer Center; University College London; The University of Texas Medical Branch; The Katholieke Universiteit Leuven; Clinic of Gynecology and Clinic of Oncology, Rigshospitalet; Copenhagen University Hospital; The Ohio State University Research Foundation; Stanford University; and the University of Kentucky. It also has strategic alliance agreement with Quest Diagnostics Incorporated to develop and commercialize up to three diagnostic tests. Vermillion, Inc. primarily serves clinical reference laboratories. The company was formerly known as Ciphergen Biosystems, Inc. and changed its name to Vermillion, Inc. in August 2007. Vermillion, Inc. was founded in 1993 and is based in Fremont, California.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements"

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING

SqueezeTrigger -- 29 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures.

Contact:

BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net www.buyins.net